Skip to main content
. 2012 May 23;17(9):1163–1170. doi: 10.1634/theoncologist.2012-0079

Figure 1.

Figure 1.

Progression-free survival times by treatment group. Group C achieved significantly longer progression-free survival than group A (5.4 vs. 8.2 months, p = .026). One patient in group C was excluded from the analysis because the date of disease progression was not confirmed.